Heart disease and strokes have declined – but remain top cause of death

A new American Heart Association report published in Circulation finds cardiovascular disease remained the leading cause of death in the U.S. with 915,973 deaths in 2023, down from 941,652 in 2022, reversing a five-year pandemic-era rise. The report notes an average cardiovascular death every 34 seconds, that cardiovascular deaths exceed combined deaths from cancer and accidents, and highlights rising stroke death rates in the 25–34 and 85+ age groups; persistent drivers include hypertension, diabetes and obesity. The release underscores prevention guidance (Life’s Essential 8) and cites a JACC 2025 study finding 99% of acute cardiovascular events were associated with at least one elevated risk factor (cholesterol, blood pressure, blood glucose, smoking).

Analysis

Market structure: Persistent high cardiovascular mortality (≈916k deaths in 2023) sustains multi-decade demand for chronic therapies, diagnostics and devices; winners include large-cap pharma with GLP-1/diabetes franchises (NVO, LLY), diagnostics (DGX, LH) and device makers (ABT, MDT, BSX) while episodic-care-focused hospitals could see slower revenue growth if prevention scales. Competitive dynamics favor integrated players that bundle meds, diagnostics and care management (CVS, UNH) who can capture margin across the care pathway; standalone acute-care providers face pricing pressure and length-of-stay risk.

Risk assessment: Tail risks include aggressive payer pushback or Medicare coverage limits on GLP-1s (high-impact, 3–18 month horizon) and potential regulatory drug-pricing reforms that compress pharma margins; a supply disruption in device manufacturing is a 1–2% revenue shock for top device names in the near term. Hidden dependencies: obesity drug adoption increases near-term drug costs for payers but could reduce stent/CABG volumes over 3–7 years; monitor GLP-1 user growth >30% y/y as a catalyst.

Trade implications: Near-term (weeks–months) favor long exposure to GLP-1 leaders and diagnostics; tactically hedge payers via put spreads on insurers for 3–9 month protection. Use options to express asymmetric upside (call spreads on NVO/LLY) and buy-dated collars on device names to protect against a 10–20% procedure-volume hit.

Contrarian angles: Consensus underestimates structural substitution risk—widespread preventive pharmacotherapy could shrink some device/SNF revenue by 5–15% over 3–5 years even as drug makers see outsized top-line. Reaction is mixed: pharma/biotech rerating may be priced for growth, while device stocks may be under-owned; mispricings exist between short-term payer pain and long-term reduction in acute-care demand.

Key Decisions for Investors

• Establish a 2.5% portfolio long in Novo Nordisk (NVO) and Eli Lilly (LLY) split 60/40, adding over next 4–8 weeks; tactically buy 6–9 month call spreads (buy ATM, sell +20% OTM) to limit cash outlay while targeting >30% upside if GLP-1 sales growth remains >25% y/y at next quarterly prints.
• Allocate 2% long to device/diagnostic basket: ABT (0.8%), MDT (0.7%), DGX (0.5%). Scale in on pullbacks of 8–15% or after quarterly results that confirm procedure volumes within ±5% of consensus; set stop-losses at -12% per name.
• Purchase a 3–6 month put spread on UnitedHealth (UNH) sized to hedge ~50% of healthcare allocation (buy 3% delta puts, sell 1% delta puts) to protect against payer margin compression from rising GLP-1 costs; unwind if CMS issues favorable coverage guidance within 60 days or if UNH volatility compresses >40%.
• Monitor CMS/Medicare rulemaking and FDA label changes over next 30–90 days as primary catalysts; if CMS signals restrictive coverage for GLP-1s, reduce NVO/LLY exposure by 40% within 5 trading days.